The afternoon of day 2 at Asembia’s AXS25 Summit offered various intriguing sessions to pick from, including one on ...

Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar ...

Chip Parkinson, CEO, GiftHealth, explains how AI, real-time data, and closer payer collaboration are driving the next phase ...

The famous trees, and the festival associated with their blossoming each spring, is part of a tradition for the global ...

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug ...

Blake Powers, CEO, Medigi, discusses how face-to-face collaboration and streamlined commercialization strategies are helping ...

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on ...

The emerging biotech scene in Chicago has the potential to develop new treatments and technologies, but funding cuts from the ...

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

In a press release, Merck KGaA CEO and chair of the executive board Belen Garijo said, “The agreed acquisition of SpringWorks is a major step in our active portfolio strategy to position Merck KGaA, ...